The partnership aims to build strong pharma and academic collaborations in sharing data and clinical samples to develop biomarker-based diagnostics for Alzheimer’s Disease.

Talk to focus on the spinout journey from drug repurposing to clinical trials for diagnosing and treating Alzheimer’s Disease

PharmaKure Submits MHRA Clinical Trial Application (CTA) for Phase 2a Clinical Trial of PK051 in Patients with Mild Cognitive Impairment Manchester, United Kingdom, 24th October 2023- PharmaKure a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Diseases (AD) and other neurodegenerative diseases, announced the Company  has filed a [...]

PharmaKure announces study success for novel blood test to identify biomarkers in patients with Alzheimer’s Disease Study confirms ALZmetrixTM whole blood test can detect people at high risk of developing full Alzheimer’s Disease Manchester, United Kingdom, 17 October 2023 – PharmaKure, a pharmaceutical company spun out from the University [...]

It is World's Alzheimer's Day today. Professor Andrew Doig and Dr. Farid Khan discuss how clinical data and biomarker data can be combined using machine learning to diagnose early stages of Alzheimer's Disease. See the Guardian Article out today. Molecular and cellular changes to the brain are [...]

Manchester, UK, 3rd July 2023: PharmaKure, a company specialising in companion diagnostics for the treatment of neurological diseases and APIS Assay Technologies Ltd, a company with scientific expertise in biomarker translation, molecular diagnostics and bioinformatics have entered into a collaboration to progress a development project for the use of [...]